Reduced Treatment-Emergent Sexual Dysfunction as a Potential Target in the Development of New Antidepressants

Table 1

Estimated proportion and relative likelihood of treatment-emergent sexual dysfunction (derived from Serretti and Chiesa [17]).

Antidepressant	𝑛 (sample)	% sexual dysfunction	Odds ratio
Moclobemide	28	0.23	.22
Agomelatine	228	3.94	.25
Amineptine	29	7.14	.46
Nefazodone	50	0.46	.46
Bupropion	645	10.38	.75
Placebo	605	14.2	1
Mirtazapine	49	2.32	2.32
Fluvoxamine	244	25.81	3.27
Escitalopram	305	37.04	3.44
Duloxetine	274	41.60	4.36
Phenelzine	24	6.43	6.43
Imipramine	54	7.24	7.24
Fluoxetine	1718	70.76	15.59
Paroxetine	1261	16.86	16.36
Citalopram	654	78.59	20.27
Venlafaxine	610	79.83	24.42
Sertraline	970	80.3	27.43